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ABSTRACT Salmonella enterica serovar Typhi is a human-restricted Gram-negative
bacterial pathogen responsible for causing an estimated 27 million cases of typhoid
fever annually, leading to 217,000 deaths, and current vaccines do not offer full pro-
tection. The O-antigen side chain of the lipopolysaccharide is an immunodominant
antigen, can deﬁne host-pathogen interactions, and is under consideration as a vac-
cine target for some Gram-negative species. The composition of the O-antigen can
be modiﬁed by the activity of glycosyltransferase (gtr) operons acquired by horizon-
tal gene transfer. Here we investigate the role of two gtr operons that we identiﬁed
in the S. Typhi genome. Strains were engineered to express speciﬁc gtr operons. Full
chemical analysis of the O-antigens of these strains identiﬁed gtr-dependent gluco-
sylation and acetylation. The glucosylated form of the O-antigen mediated enhanced
survival in human serum and decreased complement binding. A single nucleotide
deviation from an epigenetic phase variation signature sequence rendered the ex-
pression of this glucosylating gtr operon uniform in the population. In contrast, the
expression of the acetylating gtrC gene is controlled by epigenetic phase variation.
Acetylation did not affect serum survival, but phase variation can be an immune
evasion mechanism, and thus, this modiﬁcation may contribute to persistence in
a host. In murine immunization studies, both O-antigen modiﬁcations were gen-
erally immunodominant. Our results emphasize that natural O-antigen modiﬁca-
tions should be taken into consideration when assessing responses to vaccines,
especially O-antigen-based vaccines, and that the Salmonella gtr repertoire may
confound the protective efﬁcacy of broad-ranging Salmonella lipopolysaccharide
conjugate vaccines.
KEYWORDS O-antigen, Salmonella enterica, lipopolysaccharide, phase variation,
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Salmonella enterica subsp. enterica serovar Typhi is responsible for an estimated 27million new cases of typhoid fever and 217,000 deaths annually (1). Infection with
S. Typhi occurs via the fecal-oral route; after ingestion, bacteria cross the intestinal
epithelium, enter the bloodstream, and spread systemically (2). In some cases, S. Typhi
is capable of colonizing the gallbladder, leading to chronic asymptomatic shedding and
contributing to the infection cycle. Two vaccines are currently licensed for use against
S. Typhi: the parenterally administered Vi capsular polysaccharide subunit vaccine and
the orally administered live-attenuated Ty21a vaccine. Neither vaccine offers complete
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protection (3), and there is ongoing research into new vaccine formulations against S.
Typhi and other Salmonella infections (3, 4). Conjugate vaccines combining carrier
proteins with the Vi polysaccharide antigen are under development. However, Vi
expression can be up- or downregulated, and Vi-negative isolates have been isolated
from typhoid patients (5, 6). Lipopolysaccharide (LPS) is a Gram-negative bacterial
virulence factor, is a component of the outer membrane, and, in the absence of Vi, is
the predominant S. Typhi surface carbohydrate. Notably, the efﬁcacy of the S. Typhi
Ty21 vaccine is associated in part with the expression of LPS (7).
LPS is composed of a lipid A tail, which anchors the LPS into the membrane; a core
oligosaccharide; and an O-antigen side chain. The surface-exposed O-antigen side
chain protects the bacterial cell from the actions of the innate immune system (8). The
O-antigen is immunogenic and may be a functional target for novel vaccines (9, 10).
The S. enterica subspecies is comprised of over 2,600 serovars, which are based on
differences in the antigenic properties of the O- and H (ﬂagellar)-antigens and form the
basis of the Kauffman-White serotyping system (11). During natural infection, antibod-
ies are raised against LPS, and the detection of S. Typhi O-antigen antibodies forms the
basis of the diagnostic Widal test for typhoid (12). Furthermore, there is signiﬁcant
cross-reactivity between serovars sharing certain O-antigen epitopes, which may be
exploited for the development of pan-Salmonella vaccines (13). Therefore, gaining
insight into the occurrence and signiﬁcance of variation in S. Typhi O-antigen compo-
sition may enhance the understanding of S. Typhi pathogenesis and support the
development of diagnostic and intervention tools and therapies.
Modiﬁcations of LPS, including those in the O-antigen, play a role in many chronic
bacterial infections (14). O-antigen structures can be modiﬁed through several pro-
cesses, and recently, we identiﬁed and characterized numerous Salmonella gtr (glyco-
syltransferase) operons (15). Using the amino acid sequence identity of the GtrC
O-antigen-modifying proteins, we were able to group the gtr operons into 10 different
“families” and proposed that each family performs a different O-antigen modiﬁcation
(15). We additionally noted that a single Salmonella isolate may harbor multiple gtr
operons, and several families of these gtr operons can undergo phase variation (15, 16),
thus generating further potential complexity of the O-antigen presented by a popula-
tion. If, as a result, clonal bacterial populations have a nonuniform O-antigen compo-
sition, this could serve as a means of immune evasion (17–19).
The signiﬁcance of gtr-mediated O-antigen modiﬁcation for Salmonella biology is
not fully understood. In S. enterica serovar Typhimurium, speciﬁc modiﬁcations have
been implicated in gut colonization (20) and in phage resistance (21). To better
understand the extent and impact of O-antigen variation, we aimed to characterize the
activity and expression of the gtr repertoire in S. Typhi. Given that S. Typhi causes
systemic infection and that evasion of the innate immune response can contribute to
persistence, we measured the effect of gtr modiﬁcation on serum sensitivity. Further-
more, we assessed the antibody response to each O-antigen modiﬁcation in serum in
a murine immunization model.
RESULTS
The genomes of S. Typhi strains Ty2, CT18, and P-stx-12 (isolated from a chronic
carrier in India) (22) each contain two different gtr operons (15). These operons share
sequence identity between the S. Typhi strains. One operon is a family 3 gtr type with
high identity (99% amino acid) to the S. Typhimurium family 3 operon (STM0557 to
STM0559) that mediates the 1¡4 glucosylation of the O-antigen galactose sugar (20).
The second gtr operon could be grouped with the family 2 GtrCs and shared 77%
amino acid identity with a similar operon in invasive S. Typhimurium isolate D23580.
This GtrC operon has been hypothesized to acetylate the rhamnose residue of the
O-antigen (21); the S. Typhi O-antigen has a rhamnose residue, but no acetylation has
been described.
To assess the role of the S. Typhi gtr operons, we generated a set of four otherwise
isogenic S. Typhi strains with a deﬁned gtr expression pattern: STy-Basal (both gtr
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operons deleted), STy-Acetyl (expressing only family 2), STy-Gluc (expressing only
family 3), and STy-FM (both gtr operons expressed). LPSs from these isogenic strains
were extracted and compared by Western blotting (Fig. 1; see also Fig. S1 in the
supplemental material). The O-antigens of all strains reacted with commercial Salmo-
nella serum, conﬁrming that all strains expressed O-antigen (Fig. 1A) and that the
production of the long antigen structure was not affected. Factor O122 serum targets
the 1-4 glucosylation of the galactose (23), and the O-antigens of the parent S. Typhi
strain, STy-Gluc, and STy-FM reacted with this serum; strains lacking the expression of
the family 3 gtr operon did not react with this serum (Fig. 1A). Silver staining showed
that strains expressing the family 3 gtr operon had a distinct O-antigen laddering
pattern compared to that of isolates that lacked the family 3 gtr operon (Fig. S1). These
data indicate that the family 3 gtr operon of S. Typhi performs the same O-antigen
modiﬁcation as the family 3 gtr operon of S. Typhimurium, namely, 1-4 glucosylation
of the galactose. However, no visible shift in the O-antigen pattern for STy-Acetyl
compared to STy-Basal was observed, providing further evidence that family 2 GtrC
does not act as a glucosyltransferase.
Chemical analysis of the O-antigens from S. Typhi strains. To deﬁne the com-
positions and linkages of the gtr-dependent modiﬁcations, various chemical analyses
were performed on LPSs isolated from the S. Typhi parent strain and isogenic variants.
Full details are available in Fig. S2 and S3 and Tables S2 to S4 in the supplemental
material. A methylation analysis of the LPSs of these strains showed only minor
differences in the proportions of the linkages present in the polysaccharide (Table 1).
The S. Typhi parent strain and both STy-Gluc and STy-FM showed glucosylation on O-4
of galactose at 62.3%, 82.4%, and 82.5%, respectively, deduced from the galactose
linkages. Nuclear magnetic resonance (NMR) analysis revealed that the extent of
glucosylation was comparable to that derived from the methylation analysis (Table S2
and Fig. S2) (55.9% for the parent, 72.8% for STy-Gluc, and 71.2% for STy-FM).
FIG 1 Effect of gtr modiﬁcations on S. Typhi O-antigen. (A) Expression of the family 3 gtr operon leads
to recognition by O122 serum. LPS was prepared as described in Materials and Methods and run on a
Tricine–SDS-PAGE gel. Blots were probed with commercial OMA serum (top) and O122 serum (bottom).
B, STy-Basal; WT, S. Typhi parent strain BRD948 (“wild type”); Ac, STy-Acetyl; G, STy-Gluc; FM, STy-FM; Oag,
O-antigen. (B) Summary of results from chemical analysis of S. Typhi BRD948 O-antigen. OAc, acetate. (C)
Schematic of the O-antigens of engineered strains used in these studies. See Fig. S1 in the supplemental
material for additional silver stain analysis of the S. Typhi O-antigen.
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In contrast to the methylation analysis, in which O-acetyl groups are removed during
acid hydrolysis, NMR analysis of untreated LPS (no lipid A removal) permits the
identiﬁcation of acetylation. We recorded an O-acetylation signal from untreated LPSs
of both the parent S. Typhi strain and STy-FM (both harbor family 2 gtr operons) (Fig.
S2), but this signal was absent in the spectra from STy-Gluc. A further evaluation
identiﬁed a 4-linked 3-O-acetyl rhamnose and a 4-linked 2-O-acetyl-rhamnose (Fig. S3
and Table S4). The two states likely reﬂect a single modiﬁcation event, with subsequent
migration of the acetyl group (24). The parent S. Typhi strain exhibited the same pattern
of peaks in all NMR spectra as that exhibited by the STy-FM strain, with only slight
disparities in the intensities of the acetylated positions (50% and 67%, respectively) and
with O-2 and O-3 of rhamnose in approximately equal abundances. Taken together,
these data conﬁrm that the S. Typhi family 3 gtr operon mediates the 1¡4 glucosy-
lation of the galactose and show that the family 2 gtr operon acts as a rhamnose
acetyltransferase (Fig. 1B and C).
The expression patterns of the two S. Typhi gtr operons differ. The expression
of multiple gtr operons in S. enterica is controlled by phase variation (16). This
regulation is associated with a signature sequence in the regulatory region of gtrA
comprised of two binding sites for the transcriptional regulatory protein OxyR and four
GATC sites. The GATC sites are the target sequence for Dam, a “maintenance” adenine
DNA methyltransferase. The DNA methylation-dependent interaction of OxyR at the gtr
binding sites leads to epigenetic phase variation of gtr expression (15, 16). In S. Typhi,
this signature sequence is present in the family 2 gtr regulatory region, and therefore,
we predicted that this operon undergoes phase variation. In contrast, the family 3
operon has the OxyR binding sequences but only three GATC sequences, with GAAA at
the fourth, promoter-proximal, GATC sequence (Fig. 2).
The expression of both gtr operons was assessed by using single-copy transcrip-
tional lacZ fusions. In the S. Typhimurium and S. Typhi backgrounds, family 2 expression
was controlled by phase variation. The switch frequency of the on phase to the off
TABLE 1Methylation analysis of the three LPS samplesa
Modiﬁcation Glycosyl linkage
mol%
BRD948 STy-Gluc STy-FM
a t-Tyv 0.2 2.3 3.0
b 4-Rha 13.2 15.4 17.2
c t-Glc 17.6 15.2 19.4
d 2-Man or 3-Man 1.8 3.0 3.2
e 3-Gal 6.8 3.6 3.3
f 4-Glc 24.7 20.4 19.7
g 2,3-Man 15.6 16.2 15.9
h 3,4-Gal 11.3 16.8 15.6
i 4,6-Glc 1.5 1.6 0.8
aThe DG (degree of glucosylation) values [h/(h  e)  100] were 62.3% for BRD948, 82.4% for STy-Gluc, and
82.5% for STy-FM.
FIG 2 Alignment of S. Typhi gtr regulatory regions to the phase-varying regulatory region of the S.
Typhimurium family 3 gtr operon. The GATC sites are underlined, and the OxyR binding sites are outlined
in light gray boxes. The 35/10 sigma sites and the 1 transcriptional start site are indicated.
Alignment was performed by using TCOFFEE.
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phase was similar to that for the reverse switch (Table 2). Therefore, in the absence of
selective pressure, a clonal population should consist of similar numbers of cells with
and without the family 2-mediated modiﬁcation. In contrast, the strain with the lacZ
reporter for the family 3 gtr operon gave rise to only Lac colonies, indicating that the
S. Typhi family 3 gtr operon is expressed but not controlled by phase variation.
Mutation of GAAA back to GATC restored phase variation to this family 3 gtr operon
(data not shown). These data indicate that a clonal S. Typhi population is likely to have
a uniform O-antigen glycosylation pattern but is heterogeneous at the single-cell level
with respect to O-antigen acetylation.
Effect of gtr modiﬁcations on serum sensitivity. S. Typhi spreads systemically
during typhoid fever; therefore, the infecting organisms must have reliable mechanisms
for survival in the presence of components of the innate immune system. The
O-antigen can contribute to serum survival. We next assessed whether gtr expression
and its effects on O-antigen composition affect serum resistance in S. Typhi.
The serum sensitivities of the various isogenic S. Typhi strains were measured by
using commercially available human serum (Fig. 3A). The two strains containing family
3-mediated glucosylation had greater resistance to serum killing than did the STy-Basal
and STy-Acetyl strains, both of which lack glucosylation. Acetylation of the O-antigen
did not afford any signiﬁcant survival beneﬁt compared to STy-Basal under any of the
conditions tested. Taken together, these results imply that complement-mediated
killing of S. Typhi is altered by the gtr-dependent glucosylation of the O-antigen.
To corroborate differences in serum sensitivity between glucosylated and nonglu-
cosylated strains, we next assessed the binding of the C3 complement protein to the
strains. C3 initiates alternate pathway activation, leading to the formation of the
membrane attack complex (MAC). After incubation in naive human serum, cells were
exposed to ﬂuorescein isothiocyanate (FITC)-conjugated anti-C3 antibody, and the level
of surface-bound C3 was measured by ﬂow cytometry. Nonglucosylated strains (STy-
Basal and STy-Acetyl) exhibited signiﬁcantly more surface-bound ﬂuorescence than did
glucosylated strains (STy-Gluc and STy-FM) (Fig. 3B). Acetyl modiﬁcation did not
signiﬁcantly alter C3 binding (comparisons of STy-Basal to STy-Acetyl and of STy-Gluc
to STy-FM).
Recognition of S. Typhi O-antigen from a murine immunization model. We
assessed whether O-antigen modiﬁcation affected the speciﬁcity of antibodies gener-
ated in a murine immunization model. Mice were immunized with either STy-Basal (no
O-antigen modiﬁcation) or STy-FM (acetylated and glycosylated O-antigen), and serum
was collected. LPSs from the four strains with deﬁned gtr expression were used in a
Western blot assay and probed with serum from individual mice (Fig. 4). This approach
allowed the identiﬁcation of the O-antigen moieties recognized by the antibody and
discrimination from the antibody directed to the shared lipid A and core.
Irrespective of the immunizing strain, there were variations between the responses
of individual mice (Fig. 4A and B). Immunization with nonmodiﬁed O-antigen uniformly
resulted in the recognition of lipid A and core (Fig. 4A). Some animals (3/9) (e.g., Fig.
4A10) failed to show any additional recognition of the O-antigen structures. When an
O-antigen response was evident, the composition of O-antigen from the immunizing
strain was most frequently recognized (5/9) and, in some cases, was the only O-antigen
that was recognized (3/9) (e.g., Fig. 4A3) Notably, only one serum sample recognized all
four forms of S. Typhi O-antigen (Fig. 4A2).
TABLE 2 Expression of S. Typhi gtr operonsb
Strain Lac phenotype Miller units (SD)a
On-to-off switch
frequency
Off-to-on switch
frequency
LT2F2reg-lacZ Lac/Lac 1,116 (42) 3.0  103 3.3  103
LT2F3reg-lacZ Lac 763 (28) NA NA
aStandard deviations are shown in parentheses. Miller units were calculated for 100% switched-on cells for
phase-varying isolates.
bNA, not applicable.
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In contrast, in mice immunized with the STy-FM strain expressing a fully mod-
iﬁed O-antigen, the unmodiﬁed form of O-antigen was recognized in only 1/7 mice
(Fig. 4B7), suggesting a general immunodominance of the gtr-dependent modiﬁ-
cations (Fig. 4B).
All three modiﬁed O-antigen forms were recognized in only 3/7 mice (e.g., Fig 4B4).
The remaining mice produced antibodies speciﬁc for either the glucosylated or the
acetylated form despite having been immunized with a strain expressing both modi-
ﬁcations. These data predict that gtr-mediated modiﬁcations are mostly immunodom-
inant over the unmodiﬁed form (Sty-Basal) but that neither acylation nor glucosylation
is preferentially recognized after immunization with a strain expressing O-antigen with
both modiﬁcations.
DISCUSSION
The occurrence of strain- and serovar-dependent O-antigen modiﬁcation in the
salmonellae has long been recognized (25), but only recently has the potential for
gtr-mediated modiﬁcation been described for this genus (15). Here we investigated two
gtr operons in the human host-restricted pathogen S. Typhi. Our data show that the
family 3 gtr operon catalyzes 1¡4 glucosylation of galactose, as was previously
described for a family 3 gtr operon of S. Typhimurium (20). Additionally, we demon-
strate that the family 2 gtr operon is required for the acetylation of rhamnose, as was
suggested previously (21). Thus, family 2 GtrC is not a glycosyltransferase but an
FIG 3 Serum sensitivity of S. Typhi strains with different gtr modiﬁcations. (A) Results from the serum
survival assay for strains grown to stationary phase and incubated in 50% serum. Different symbols
represent the data obtained from individual experiments. One-way analysis of variance and Tukey
postanalysis were performed by using GraphPad Prism (version 5.0d). *, P  0.05. (B) Binding of C3
protein to S. Typhi strains with different O-antigen compositions. Strains were incubated in human
serum, followed by anti-C3 FITC-conjugated antibody, and surface-bound ﬂuorescence was measured by
ﬂow cytometry. Data from four experiments are combined. MESF, molecules of equivalent soluble
ﬂuorochrome. One-way analysis of variance and Tukey postanalysis were performed by using GraphPad
Prism (version 5.0d). *, P  0.05; **, P  0.01; ***, P  0.001. Error bars indicate means  standard errors
of the means.
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acyltransferase, and the gtr acronym thus reﬂects only proximity to (remnant) gtrAB
genes (15). Galactose glucosylation in the S. Typhi O-antigen was previously reported
(25), but, to our knowledge, this is the ﬁrst report of rhamnose acetylation in S. Typhi.
Acetylation of the family 3-dependent glucose modiﬁcation may also occur, but the
genes encoding this process remain to be identiﬁed (25, 26).
Acetylation of the rhamnose moiety will be heterogeneous in a bacterial population
due to phase variation of the expression of the family 2 gtr operon. This is consistent
with a role in, and a mechanism of, immune evasion (19). In contrast, the STy family 3
gtr regulatory region deviates from the known phase variation signature sequence in
one GATC sequence, which caused an abrogation of phase variation. Thus, glucosyla-
tion should be uniformly expressed among cells in a population, likely contributing to
the high degree of glucosylation observed in S. Typhi O-antigen compared to those of
other Salmonella serovars (26, 27). The sequence variation associated with this lack of
phase variation is present in both the S. Typhi CT18 and Ty2 genomes.
O-antigen glucosylation has implications for virulence in nontyphoidal serovars. In
S. Typhimurium, family 3-dependent glucosylation is associated with increased persis-
tence in the mouse intestine (20), and glucosylation of the S. enterica serovar Enteritidis
O-antigen is associated with an increase in virulence in a chicken-to-egg transmission
model (27). The role that we identiﬁed for family 3-dependent glucosylation in serum
resistance adds to the evidence that O-antigen glucosylation can affect Salmonella-host
interactions (14, 28). This ﬁnding does not exclude further beneﬁts of this modiﬁcation
for S. Typhi.
Antibody recognition of a pathogen is an important feature of the clearance of
infection. In S. Typhi, the Vi capsular polysaccharide contributes to immune evasion
FIG 4 Recognition of S. Typhi O-antigen by serum in a murine immunization model depends on the
O-antigen composition of the immunizing strain. In an LPS Western blot, LPSs from different strains were
probed with serum from mice immunized with either Sty-Basal (A) or STy-FM (B). Panel A1 shows the
reactivity of pooled serum from the PBS-immunized control group, and each following panel (panels 2
to 10) represents serum from an individual mouse. Panel B1 shows the reactivity of commercial OMA
serum, which recognizes several Salmonella serovars; each following panel represents serum from an
individual mouse. Lanes 1 to 4 in each panel show LPS from the following strains, respectively: STy-Basal,
STy-Acetyl, STy-Gluc, and STy-FM.
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(29), and antigen O9 antibodies can affect antibody-mediated serum resistance. This
role of O9 antibodies may be relevant for antibody-mediated killing when there is
reduced Vi capsule expression during the infection cycle (30, 31). Our data highlight
that both gtr-mediated O-antigen modiﬁcations can inﬂuence antibody recognition of
the O-antigen. The trend from the murine model was that immunization with a strain
with modiﬁed O-antigen generated antibodies that predominantly recognized the
modiﬁed version of Salmonella O-antigen and did not recognize the basal, unmodiﬁed
O-antigen. These modiﬁcations thus could impact antibody-dependent killing mecha-
nisms during S. Typhi infection.
In other Salmonella serovars, dominant epitopes induced by O-antigen modiﬁcation
have been shown to be relevant for eliciting a protective immune response. For
example, OafA-dependent acetyl modiﬁcation of abequose is required for protective
antibodies against S. Typhimurium (32, 33). A protective S. enterica serovar Paratyphi A
glycoconjugate LPS vaccine required acetylation, which is likely dependent on the
described rhamnose acetylation modiﬁcation (34, 35). Based on the data presented
here linking rhamnose acetylation to the family 2 gtr operon, this can now be attributed
to the family 2 gtr operon harbored by the S. Paratyphi A genome (15). Rhamnose
acetylation was also implicated in the strain-speciﬁc dominant epitope of the invasive
S. Typhimurium D23580 isolate (33), which can be attributed to the phage-borne family
2 gtr operon that is expressed in this speciﬁc strain (21). However, detailed analyses in
the context of the host, disease, and serovars are needed to further clarify the impact
of O-antigen acetylation and glucosylation (36, 37).
Our results expand the body of evidence demonstrating that O-antigen composition
in Salmonella impacts host-pathogen interactions during infection. Strains within a
speciﬁc serovar may have different repertoires of O-antigen-modifying genes, and
expression may ﬂuctuate by phase variation. Consequently, antibody generated by
primary infection or immunization may not wholly recognize subsequent infections by
the same serovar. Indeed, disease-associated S. Typhi strains are not clonal, and the
genetic repertoire of O-antigen-modifying genes may vary (15, 38, 39). Furthermore,
the Ty21a oral vaccine elicits a strong O-antigen antibody response (13), and thus, any
factors that modify this response may impact serovar and strain cross-reactivity. In
conclusion, we suggest that O-antigen modiﬁcation repertoires may need to be con-
sidered in vaccine design to enhance efﬁcacy against a broad range of S. Typhi isolates
and phenotypes.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Strains were grown in LB unless mentioned otherwise. For
S. Typhi BRD948, medium was supplemented with an Aro mix (ﬁnal concentrations of 40 M
L-phenylalanine, 40 M L-tryptophan, 1 M para-aminobenzoic acid, 1 M 2,3-dihydroxybenzoic acid,
and 40 M tyrosine). The following antibiotics were used: tetracycline at 15 g/ml, ampicillin at 100
g/ml, chloramphenicol at 34 g/ml for vectors and 8 g/ml for chromosomal inserts, and kanamycin
at 30 g/ml. S. Typhi BRD948 and its derivatives were conﬁrmed to be Vi positive (Vi) by serum
agglutination (Vi antiserum; Statens Serum Institute). For analysis of LacZ expression, strains were grown
on minimal M9 medium (Sigma, Gilingham, UK) with 0.2% glucose (S. Typhimurium) or LB (S. Typhi) with
40 g/ml X-gal (5-bromo-4-chloro-3-indolyl--D-galactoside; Melford). Strains are listed in Table S1 in the
supplemental material.
Molecular biology, strain construction, and mutagenesis. Standard molecular biology techniques
were used (40). Details on vectors and primers used in these studies are provided in Table S1 in the
supplemental material. Strains containing a lacZ reporter fusion on the chromosome at the attB site were
generated by using the CRIM (conditional-replication, integration, and modular) system (41), using vector
pMV243 (42). Allelic replacement was used to introduce mutations into the chromosome (43). Antibiotic
resistance cassettes were obtained from Tn10 for Tcr and pKD4 for Kmr (43). Unmarked strains were
generated by the removal of the pKD13-derived Kmr cassette by Flp recombinase expressed from pCP20
(44). Vectors and primer details are provided in Table S1.
Analysis of gene expression. -Galactosidase assays on strains with lacZ reporter fusions were
performed as described previously by Miller (45). Cultures derived from two independent colonies were
grown in M9 minimal medium with glucose. Samples were collected at least in triplicate between optical
density at 600 nm (OD600) values of 0.3 to 1.5 for measurement of -galactosidase activity, given in Miller
units. The switch frequency of phase variation was calculated for two independent colonies each for a
Lac or Lac phenotype, as described previously (46). The switch frequency is expressed as the number
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of cells that have a changed expression state (M) over the total number of cells (n), divided by the
number of generations (g).
LPS extraction and visualization. Crude LPS extracts were prepared as described previously (15)
and separated on a Tricine–SDS-PAGE gel, and O-antigen was visualized by using a silver stain (15) or
Western blotting. These crude extracts can incidentally contain contaminating macromolecules that are
apparent on the gels or Western blots. For Western blot analyses, samples were transferred onto a
polyvinylidene diﬂuoride (PVDF) membrane and blocked with 5% milk in phosphate-buffered saline-
Tween (PBS-T). A O12-OMA polyvalent antiserum mixture for salmonella O-antigen from groups A, B, D,
E, and L (Statens Serum Institute) or O122 serum was used to probe blots as indicated, using secondary
goat anti-rabbit IgG-horseradish peroxidase (HRP) (catalog number A0545; Sigma). When mouse serum
was used, goat anti-mouse IgG-HRP (catalog number A1068) served as a secondary antibody. The
Luminato Western HRP substrate (Millipore) was used for detection.
Serum sensitivity assay. Human serum was purchased from Sigma (catalog number H4522). This
serum failed to agglutinate the S. Typhi strains. S. Typhi strains were grown overnight and then diluted
to an OD600 of 0.5 in PBS. Five microliters of bacteria was added to 45 l of serum diluted in PBS, and
the mixture was incubated for 1 h at 37°C. Dilutions were performed to determine CFU. Survival was
determined by comparing counts to those obtained from a control that was incubated in 45 l PBS.
Experiments were performed in duplicate and repeated at least three times.
C3 binding to the bacterial surface. Experiments were performed by using stationary-phase
bacteria. Methods were adapted from those described previously by MacLennan et al. (47), using
quantities similar to those used in the serum sensitivity experiments. Brieﬂy, bacteria were incubated
with full-strength human serum followed by incubation with polyclonal rabbit anti-human C3c FITC
antibody (catalog number F-0201; Dako). A Beckman Coulter CyAn ADP analyzer was used to collect data.
A Bangs FITC-5 MESF (molecules of equivalent soluble ﬂuorochrome) kit (catalog number 555) allowed
the standardization of ﬂuorescence across experiments.
Generation of murine immune serum. Female Slc11a1D169 (Nramp1s) C57BL/6 CD45.1 mice were
obtained from Charles River UK, housed under speciﬁc-pathogen-free conditions, and used at 6 to 10
weeks of age. All experiments were approved by the University of York Animal Welfare and Ethical
Review Body and performed under a UK Home Ofﬁce license. For immunizations, bacteria from cultures
grown overnight were diluted to an OD600 of 1.0 in PBS. Two hundred microliters was given intraperi-
toneally (i.p.), resulting in an inoculum ranging from 8.12  107 to 2.56  108 CFU. Twenty-eight days
after immunization, mice were exsanguinated by cardiac puncture under terminal anesthesia. Serum was
obtained by allowing the collected blood to coagulate overnight at 4°C and then centrifuging the blood
at 2,000 rpm for 2 min. The serum layer was then removed and stored at20°C until use. Nine mice were
immunized with the STy-Basal strain, and seven were immunized with the STy-FM strain.
SUPPLEMENTAL MATERIAL
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